Analyst firms · BofA Securities · RMD

BofA Securities RMD price target and rating history

ResMed Inc. (RMD) · Health Care

BofA Securities rates ResMed Inc. (RMD) Buy with a $260 price target, as of its latest action on Oct 20, 2022. It has published 3 rating actions on RMD since January 2022, including 3 upgrades and 0 downgrades. Across 5 firms with a RMD price target in the last 12 months, the median target is $235.

Current rating
Buy
Price target
$260
Median target, all firms
$235
Actions on RMD
3

BofA Securities price target on RMD

$260$255$2502023202420252026
BofA Securities price target on RMD, each point a stated target, January 2022 to October 2022.

Every BofA Securities rating on RMD

How other firms rate RMD

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Canaccord GenuityHoldNov 2, 2026
RBC Capital MarketsOutperform$262Sep 15, 2026
Rothschild & Co RedburnNeutral$230Aug 19, 2026
CitigroupNeutral$235Jul 13, 2026
Morgan StanleyEqual-Weight$230Jun 17, 2026
Robert W. BairdNeutral$275Dec 16, 2025

Questions about BofA Securities and RMD

What is BofA Securities's price target for RMD?
BofA Securities's latest stated price target for ResMed Inc. (RMD) is $260, from its action on Oct 20, 2022.
What is BofA Securities's rating on RMD?
BofA Securities rates RMD Buy, a bullish rating, as of Oct 20, 2022.
When did BofA Securities last change its view on RMD?
On Oct 20, 2022, BofA Securities upgrades to Buy from Neutral, price target $245 to $260.
How does BofA Securities's RMD target compare with other analysts?
Across 5 firms with a RMD price target in the last 12 months, the median target is $235.

More RMD rating histories

All BofA Securities ratingsRMD news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.